


Accepted Manuscript

Plasma filtration for the controlled removal of liposomal therapeutics - from the apheretic site of view

M. Blaha, J. Martinkova, M. Lanska, S. Filip, J. Malakova, O. Kubecek, J. Bezouška, J. Spacek



PII: S1567-5688(17)30064-8

DOI: [10.1016/j.atherosclerosissup.2017.05.022](https://doi.org/10.1016/j.atherosclerosissup.2017.05.022)

Reference: ATHSUP 314

To appear in: *Atherosclerosis (Supplements) (Component)*

Please cite this article as: Blaha M, Martinkova J, Lanska M, Filip S, Malakova J, Kubecek O, Bezouška J, Spacek J, Plasma filtration for the controlled removal of liposomal therapeutics - from the apheretic site of view, *Atherosclerosis (Supplements) (Component)* (2017), doi: 10.1016/j.atherosclerosissup.2017.05.022.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Plasma filtration for the controlled removal of liposomal therapeutics

- from the apheretic site of view

M. Blaha^{a*}, J. Martinkova^b, M. Lanska^a, S. Filip^b, J. Malakova^c, O. Kubecek^b, J. Bezouška^b, J. Spacek^d

^a 4th Department of Internal Medicine – Hematology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic;

^b Department of Oncology and Radiotherapy, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic;

^c Department of Clinical Biochemistry and Diagnostics of University Hospital in Hradec Králové, Czech Republic;

^d Department of Gynecology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic;

*Corresponding author:

Prof. Milan Blaha. MD., Ph.D.

4th Department of Internal Medicine – Hematology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic;

Tel.: +420 495834555

e-mail: blaham@email.cz

Abstract

Introduction: Nanoparticle-based drug delivery systems can overcome the dose-limited toxicity of cytostatics. Pegylated doxorubicin-containing liposomes (PLD) are able to reduce cardiotoxicity. PLD quickly (in 2 days) attains therapeutic concentration in tumorous tissue (kinetic targeting), while its distribution in normal tissue, which is a cause of mucocutaneous toxicity (MCT), is delayed. We examined PLD extracorporeal removal effectivity, using plasma

Download English Version:

<https://daneshyari.com/en/article/8657303>

Download Persian Version:

<https://daneshyari.com/article/8657303>

[Daneshyari.com](https://daneshyari.com)